- Home
- SENEA vs PRAX Comparison
SENEA vs PRAX Comparison
Compare SENEA & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- PRAX
- Stock Information
- Founded
- SENEA 1949
- PRAX 2015
- Country
- SENEA United States
- PRAX United States
- Employees
- SENEA N/A
- PRAX N/A
- Industry
- SENEA Packaged Foods
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- PRAX Health Care
- Exchange
- SENEA Nasdaq
- PRAX Nasdaq
- Market Cap
- SENEA 629.3M
- PRAX 599.7M
- IPO Year
- SENEA N/A
- PRAX 2020
- Fundamental
- Price
- SENEA $90.29
- PRAX $42.34
- Analyst Decision
- SENEA
- PRAX Strong Buy
- Analyst Count
- SENEA 0
- PRAX 11
- Target Price
- SENEA N/A
- PRAX $114.73
- AVG Volume (30 Days)
- SENEA 85.0K
- PRAX 294.2K
- Earning Date
- SENEA 06-12-2025
- PRAX 08-12-2025
- Dividend Yield
- SENEA N/A
- PRAX N/A
- EPS Growth
- SENEA N/A
- PRAX N/A
- EPS
- SENEA 5.90
- PRAX N/A
- Revenue
- SENEA $1,578,887,000.00
- PRAX $8,122,000.00
- Revenue This Year
- SENEA N/A
- PRAX N/A
- Revenue Next Year
- SENEA N/A
- PRAX $6,358.50
- P/E Ratio
- SENEA $15.30
- PRAX N/A
- Revenue Growth
- SENEA 8.25
- PRAX 270.02
- 52 Week Low
- SENEA $56.36
- PRAX $26.70
- 52 Week High
- SENEA $96.79
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- SENEA 47.17
- PRAX 54.36
- Support Level
- SENEA $87.99
- PRAX $41.64
- Resistance Level
- SENEA $94.00
- PRAX $44.99
- Average True Range (ATR)
- SENEA 3.17
- PRAX 2.55
- MACD
- SENEA -0.60
- PRAX -0.11
- Stochastic Oscillator
- SENEA 43.92
- PRAX 51.07
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.